Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma

NCT03434262 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT03434262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03434262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 1
Overall status
Completed
Start date
March 5, 2018
Completion date
May 24, 2024
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic ependymoma, anaplastic ganglioglioma, anaplastic meningioma, anaplastic oligodendroglioma, atypical teratoid/rhabdoid tumor, brain cancer, brain tumor, central nervous system neoplasms, choroid plexus carcinoma, cns embryonal tumor with rhabdoid features, cns tumor, embryonal tumor of cns, embryonal tumor with multilayered rosettes (etmr), embryonal tumor, nos, ependymoma, ependymoma, nos, who grade ii, ependymoma, nos, who grade iii, ependymoma, recurrent, ependymoma, rela fusion positive, ganglioneuroblastoma of central nervous system, glioblastoma, glioblastoma, idh-mutant, glioblastoma, idh-wildtype, glioma, glioma, diffuse midline, h3k27m-mutant, glioma, high grade, glioma, malignant, glioma, recurrent high grade, glioma, recurrent malignant, medulloblastoma, medulloblastoma, chromosome 9q loss, medulloblastoma, g3/g4, medulloblastoma, group 3, medulloblastoma, group 4, medulloblastoma, non-wnt non-shh, nos, medulloblastoma, non-wnt/non-shh, medulloblastoma, ptch1 mutation, medulloblastoma, shh-activated and tp53 mutant, medulloblastoma, shh-activated and tp53 wildtype, medulloblastoma, wnt-activated, medulloblastoma; unspecified site, medulloepithelioma, neoplasms, neoplasms, neuroepithelial, neuroblastoma. cns, neuroepithelial tumor, neuroepithelial tumor, high grade, papillary tumor of the pineal region (high-grade only), pediatric brain tumor, pineal parenchymal tumor of intermediate differentiation (high-grade only), pineoblastoma, pleomorphic xanthoastrocytoma, anaplastic, primitive neuroectodermal tumor, recurrent medulloblastoma, refractory brain tumor